WallStSmart

TechCreate Group Ltd. (TCGL)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 7778% more annual revenue ($258.90M vs $3.29M). ZEPP leads profitability with a -15.5% profit margin vs -20.7%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

TCGL

Avoid

22

out of 100

Grade: F

Growth: 5.3Profit: 3.5Value: 5.0Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for TCGL.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TCGL0 strengths · Avg: 0/10

No standout strengths identified

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

TCGL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
2.9%3/10

Operating margin of 2.9%

Price/BookValuation
4321.0x2/10

Trading at 4321.0x book value

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : TCGL

Revenue growth of 10.4% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : TCGL

The primary concerns for TCGL are EPS Growth, Return on Equity, Operating Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

TCGL profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 22/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

TechCreate Group Ltd.

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

TechCreate Group Ltd. (TCGL) is a pioneering technology company focused on delivering cutting-edge software solutions and transformative digital services tailored for diverse industries. By harnessing advancements in artificial intelligence and machine learning, TechCreate enhances operational efficiency and empowers clients in their digital transformation journeys. The company's extensive portfolio features bespoke software applications, cloud solutions, and robust enterprise resource planning systems, designed to serve the unique needs of both small enterprises and large corporations. Strategically positioned within the dynamic global technology sector, TechCreate is dedicated to providing scalable and impactful solutions that address the evolving requirements of its clientele.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?